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Abstract: Brain metastasis is a major cause of mortality in melanoma patients. The blood-brain barrier (BBB) pre-
vents most anti-tumor compounds from entering the brain, which significantly limits their use in the treatment of 
brain metastasis. One strategy in the development of new treatments is to assess the anti-tumor potential of drugs 
currently used in the clinic. Here, we tested the anti-tumor effect of the BBB-penetrating antipsychotic trifluopera-
zine (TFP) on metastatic melanoma. H1 and Melmet1 human metastatic melanoma cell lines were used in vitro and 
in vivo. TFP effects on viability and toxicity were evaluated in proliferation and colony formation assays. Preclinical, 
therapeutic efficacy was evaluated in NOD/SCID mice, after intracardial injection of tumor cells. Molecular studies 
using immunohistochemistry, western blots, immunofluorescence and transmission electron microscopy were used 
to gain mechanistic insight into the biological activity of TFP. Our results showed that TFP decreased cell viability and 
proliferation, colony formation and spheroid growth in vitro. The drug also decreased tumor burden in mouse brains 
and prolonged animal survival after injection of tumor cells (53.0 days vs 44.5 days), TFP treated vs untreated 
animals, respectively (P < 0.01). At the molecular level, TFP treatment led to increased levels of LC3B and p62 in 
vitro and in vivo, suggesting an inhibition of autophagic flux. A decrease in LysoTracker Red uptake after treatment 
indicated impaired acidification of lysosomes. TFP caused accumulation of electron dense vesicles, an indication of 
damaged lysosomes, and reduced the expression of cathepsin B, a main lysosomal protease. Acridine orange and 
galectin-3 immunofluorescence staining were evidence of TFP induction of lysosomal membrane permeabilization. 
Finally, TFP was cytotoxic to melanoma brain metastases based on the increased release of lactate dehydrogenase 
into media. Through knockdown experiments, the processes of TFP-induced lysosomal membrane permeabilization 
and cell death appeared to be STAT3 dependent. In conclusion, our work provides a strong rationale for further clini-
cal investigation of TFP as an adjuvant therapy for melanoma patients with metastases to the brain.
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Introduction
Brain metastases are recognized as one of the 
main causes of mortality in patients with mela-
noma, occurring in more than 50% of melano-
ma patients during their course of the disease 
[1]. Treatment failure is thought to be due to 
their large size at the time of neurological pre-
sentation [2] and that they are highly radiore-
sistant [3]. Thus, although management of 
melanoma brain metastases is comprehen-
sive, typically including surgical resection, ste-
reotactic radiosurgery, whole-brain radiothera-
py (WBRT) and cytotoxic chemotherapy, pro- 
gnosis remains poor, with a median patient sur-
vival of 4 to 5 months [4].
Targeted therapies, such as BRAF and MEK 
inhibitors, have been used in clinical trials [5], 
and have to some extent improved clinical out-
come of melanoma patients with metastatic 
disease [6]. However, most of these patients 
will develop resistance to therapy within a few 
months [7]. Although recent advances in BRAF 
and immune checkpoint therapies to some 
extent have improved patient survival, the exis-
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tence of the blood brain barrier (BBB) limits 
their penetrance into the brain [8] and thus, 
their efficacy in the treatment of brain metasta-
sis. Molecules that penetrate the BBB more 
easily are therefore likely to improve treatment 
efficacy. 
Autophagy is a lysosome-dependent process, 
in which metabolic wastes, toxic protein aggre-
gates, nonfunctional organelles and intracellu-
lar pathogens are degraded for recycling [9]. 
The lysosome, one of the cytoplasmic mem-
brane-bound organelles, has previously been 
looked upon as a waste bag because of its 
roles in the late stage of autophagy [10]. 
Recently, several studies have shown that lyso-
somes may be involved in many other cellu- 
lar processes, including regulation of cellular 
homeostasis [11]. It has also been demonstrat-
ed that lysosomes are involved in cell death, 
which is closely associated with lysosomal 
membrane permeabilization (LMP) [12]. Lyso- 
somes contain more than 50 acidic hydrolases, 
which are critical for degradation [13]. LMP is a 
process in which destabilization of the lyso-
somal membrane causes leakage of lysosomal 
contents into the cytoplasm, ultimately result-
ing in cell death [14]. Among the lysosomal con-
tents that lead to cell death, cathepsin B and D 
are the most important.
Trifluoperazine (TFP) has been used in the cli- 
nic for the treatment of schizophrenia for more 
than half a century. It is a typical antipsychotic 
compound of the phenothiazine chemical class, 
with a favorable size of 407.5 Da, enabling the 
drug to penetrate an intact BBB [15, 16]. 
Recent drug repurposing studies have shown 
that TFP has efficient anti-tumor effects in vari-
ous tumor types, including lung cancer, malig-
nant peripheral nerve sheath tumors and leu-
kemia [17-19]. In a recent study, we demo- 
nstrated that TFP increased the radiosensitivity 
of glioblastoma (GBM) in vitro and in vivo, 
resulting in increased tumor cell death and pro-
longed animal survival [20]. However, we did 
not investigate a role for lysosomes in TFP-
induced cell death. 
In this study, we demonstrate that TFP has anti-
tumor effects on melanoma brain metastases 
in vitro and in vivo, using a well-established ani-
mal model of experimental melanoma brain 
metastases. Furthermore, we demonstrate a 
relationship between the cytotoxic effects of 
TFP on melanoma brain metastases and LMP. 
Materials and methods
Cell lines
The H1 and H3 cell lines were established in 
our laboratory from patient biopsies of human 
melanoma brain metastasis, as previously 
described [21, 22]. The Melmet 1 and Melmet 
5 cell lines were obtained from Prof. Ø. Fodstad, 
University of Oslo, Norway. The H1 cells were 
transduced with two lentiviral vectors, encod-
ing Dendra (a green fluorescent protein (GFP) 
variant) and luciferase to obtain the H1_DL2 
cell line. The cell lines were cultured with DMEM 
supplemented with 10% heat-inactivated new-
born calf serum, four times the prescribed con-
centration of non-essential amino acids, 2% 
L-glutamine, penicillin (100 IU/mL) and strepto-
mycin (100 μL/mL; all reagents from Cambrex, 
East Rutherford, NJ, USA), hereafter named 
complete DMEM. Cells were incubated in a 
standard tissue culture incubator at 37°C, 
100% humidity and 5% CO2. 
Cell viability assay
The H1, H3, Melmet 1 and Melmet 5 cell lines 
were suspended in complete DMEM and seed-
ed (5 × 103 cells/well) into 96-well, flat-bot-
tomed dishes (Nunc, Roskilde, Denmark). After 
incubation overnight at 37°C, cells were pre-
treated with PBS (control) or TFP (1-30 µM). 
After 24 h of culture, cells were incubated for 
an additional 2 h at 37°C with 100 µL of com-
plete DMEM containing 0.1 mg/mL of Resazur- 
in solution (Sigma-Aldrich, St. Louis, MO, USA), 
and absorbance was measured at a wave-
length of at dual mode 560/590 nm with a 
scanning multiwell spectrophotometer (Victor 3 
1420 multi-label counter, Perkin Elmer, Wal- 
tham, MA, USA). Each experiment was repeat-
ed 3 times.
Cell proliferation
Cell proliferation before and after treatment 
with TFP was studied using a cell counting 
assay. Briefly, H1 and Melmet 1 cells (2 × 104 
cells/well) were plated in 12-well plates (Nunc). 
The cell monolayers were then treated with 
PBS (control), 3 µM or 6 µM TFP. On days 1, 2, 
3 and 4 after treatment start, cells were tryp-
sinized, stained with 0.4% trypan blue and 
counted. Growth curves were generated using 
GraphPad Prism 6 (GraphPad Software, Inc., 
San Diego, CA). Each experiment was repeated 
3 times.
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Colony formation assay
The H1, H3, Melmet 1 and Melmet 5 cells were 
each plated in six-well plates (Nunc, 3 × 103 
cells/well). After treatment with PBS (control), 3 
µM or 6 µM TFP for 24 h, the cells were rinsed 
in PBS 3 times and incubated with complete 
DMEM for 14 days. The colonies were then 
rinsed in PBS 3 times, fixed with 4% parafor-
maldehyde, rinsed with PBS 3 times, and 
stained with 0.1% crystal violet and counted. All 
colonies containing more than 50 cells were 
counted. Each experiment was repeated 3 
times.
Spheroid growth
Multicellular spheroids from H1 and Melmet 1 
cells were prepared as described below. Briefly, 
3 × 103 cells in 100 μL of complete DMEM were 
seeded per well in Costar 96-well round bottom 
ultra-low attachment plates (Corning Inc., 
Corning, NY, USA). Cells were pelleted at 1000 
× g for 15 min, and incubated for 5 days, after 
which they had rounded up into spheroids. The 
spheroids were exposed to PBS (control), 5 µM 
or 10 µM TFP for 15 days. Changes in two 
orthogonal spheroid diameters were measured 
for each spheroid using an IncuCyte Zoom live 
cell imaging system (Essen BioScience, Ann 
Arbor, MI, USA). Each experiment was repeated 
3 times. For each cell line, 3 spheroids were 
measured per experiment. 
Intracardial tumor cell injections and drug 
therapy
16 female NOD/SCID mice (6-8 weeks old) 
were anesthetized and fixed in a supine posi-
tion on a heating pad to maintain a core tem-
perature at 37°C. 5 × 105 H1_DL2 cells in 0.1 
mL PBS were injected during 30 sec into the 
left cardiac ventricle of each mouse using a 
30G insulin syringe (Omnican50, B. Brain Me- 
dical AS, Vestskogen, Norway), by ultrasound 
guidance (Vevo(R) 2100 Imaging System 230 V, 
Visual Sonics Inc., Toronto, Canada). After two 
weeks, the mice were randomized into two 
groups. The first group received TFP intraperito-
neally (i.p.) 5 days/week (1 mg/kg in 100 mL 
PBS, 8 mice). The second group received 100 
mL of PBS i.p. 5 days/week (control group, 8 
mice).
Mice were euthanized if they showed weight 
loss of more than 20% of their body weight, or 
upon signs of severe neurological symptoms. 
The brains were harvested, fixed in 4% para- 
formaldehyde, and embedded in paraffin.
Magnetic resonance imaging (MRI)
Brain metastasis development in the NOD/
SCID mice after intracardiac cell injection was 
studied using a 7 Tesla small-animal MR scan-
ner (Bruker PharmaScan; Bruker BioSpin MRI, 
Ettlingen, Germany) equipped with a 1-channel 
circular transmitter coil and a 4-channel re- 
ceiver surface coil. Coronal, T1 weighted (T1w) 
images were taken before and after injection 
of Omniscan contrast agent (GE Healthcare, 
Oslo, Norway), and images were produced with 
the following RARE sequence scan parame- 
ters: Field of view (FOV) 20 mm × 16 mm, matrix 
size 256 × 256, 0.5 mm slice thickness, repeti-
tion time (TR) 1000 ms, echo time (TE) 9 ms, 
flip angle (FA) 90°, 4 averages and scan time 3 
min 12 sec. T2 weighted (T2w) coronal images 
were obtained with the following RARE se- 
quence scan parameters: FOV 20 mm × 16 
mm, matrix size 256 × 256, 0.5 mm slice thick-
ness, TR 3200 ms, TE 38 ms, FA 90°, 4 aver-
ages, scan time 6 min 49 sec.
Visualization of MR images and quantification 
of tumor numbers and volumes (V = 4/3 × pi × 
r3) were performed using the 32-bit OsiriX 
freeware, version 5.8.1 (Pixmeo SARL, Geneva, 
Switzerland).
Immunohistochemical analysis
Paraffin-embedded mouse brain samples were 
sectioned (4 μm) and mounted onto microscop-
ic slides. For histological assessment, sections 
were deparaffinized and stained with Hema- 
toxylin and Eosin (H&E). For immunohistochem-
istry, deparaffinized sections were incubated 
with the primary antibody at 4°C overnight 
(LC3BI/II, 1:3200; Ki67, 1:800; P62, 1:250; all 
antibodies from Cell Signaling Technology, Be- 
verly, MA, USA), rinsed with PBS, and incuba- 
ted with goat anti-rabbit secondary antibody 
(ZSGB-Bio; Beijing, China). Three representa-
tive images from each section were taken 
under bright field microscopy (Leica DMi8, 
Leica Microsystems, Wetzlar, Germany). For 
each image, positively stained nuclei were 
counted using ImageJ software (V1.8.0, Na- 
tional Institutes of Health; Bethesda, MD, USA). 
Positively Ki67-stained cells are presented as a 
percentage of a total number of cells counted. 
Staining of cancer cells was scored as follows: 
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0, no staining; 1, weak staining in < 50% of 
cells; 2, weak staining in ≥ 50% of cells; 3, 
strong staining in < 50% of cells; and 4, strong 
staining in ≥ 50% of cells. For each group, 3 
random mice were checked, and for each 
mouse, 3 images were obtained.
Western blot analysis
The H1, H3, Melmet 1 and Melmet 5 cell lines 
were grown in 6-well plates until the monolay-
ers were 70-80% confluent. The cells were then 
treated with PBS (control), 3 µM or 6 µM TFP 
and incubated for 24 h. Cells were collected 
and whole-cell lysates (40 μg) were prepared 
from all cell lines using RIPA buffer (Thermo 
Fisher Scientific, Waltham, MA, USA). Proteins 
were resolved by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and transferred 
to a polyvinylidene difluoride membrane. Me- 
mbranes were blocked with 5% powdered sk- 
im milk dissolved in Tris-buffered saline (0.02 
M Tris-HCl (pH 7.5), 0.15 M NaCl and 0.1% 
Tween20), and subsequently incubated with 
primary (Cell Signaling Technology) and indicat-
ed secondary antibodies (Thermo Fisher Sci- 
entific). Proteins on membranes were visual-
ized using a chemiluminescence detection sys-
tem, SuperSignal West Femto (Thermo Fis- 
her Scientific), and imaged with the LAS-3000 
image analysis system (Fujifilm, Tokyo, Japan). 
The following primary antibodies were used for 
western blot: GAPDH, LC3BI/II, P62, STAT3 and 
phosphorylated STAT3 (Tyr705).
Autophagic flux measurement
The Autophagy Tandem Sensor RFP-GFP-LC3B 
Kit (Thermo Fisher Scientific) enables monitor-
ing of the various stages of autophagy through 
LC3B localization. The fluorescence from the 
sensor is based on the pH difference between 
the autolysosome and the autophagosome. By 
combining an acid-sensitive green fluorescent 
protein (GFP) with an acid insensitive red fluo-
rescent protein (RFP), the change in LC3B local-
ization from the autophagosomes (with a neu-
tral pH) to the autolysosomes (with an acidic 
pH) can be visualized by imaging the specific 
loss of the GFP fluorescence, leaving only red 
fluorescence.
Briefly, cells were incubated with the RFP-GFP-
LC3B reagent (2 µL/10,000 cells) in 24-well 
plates. After 48 h, cells were trypsinized, centri-
fuged, rinsed and cultured on coverslips in 
24-well plates (1,000 cells/well). Cells were 
incubated overnight and then treated with 3 µM 
TFP or PBS for 24 h. Cells were fixed in 4% para-
formaldehyde and antifade mounting medium 
(Thermo Fisher Scientific) was added. Images 
were captured using a Leica TCS SP5 confocal 
microscope (Leica Microsystems). Each experi-
ment was repeated 3 times.
LysoTracker staining
LysoTracker Red (Thermo Fisher Scientific) was 
used as a probe for lysosomes to study poten-
tial changes in acidification and morphology 
after treatment. Following treatment with PBS 
(control) or 3 µM TFP for 24 h, H1 and Melmet 1 
cells were treated with LysoTracker Red (final 
concentration of 66 nM). After incubation for 
30 min at 37°C, cells were rinsed with PBS, and 
fixed with 4% paraformaldehyde at room tem-
perature for 15 min. Antifade mounting medi-
um (Thermo Fisher Scientific) was added, and 
the cells were imaged using a Leica TCS SP5 
confocal microscope (Leica Microsystems). 
Each experiment was repeated 3 times, and 3 
images were obtained in each group for each 
experiment.
Transmission electron microscopy (TEM)
TEM was used to study potential changes in the 
ultrastructure of cells after treatment. H1 and 
Melmet 1 cells treated with PBS (control) or 3 
µM TFP for 24 h were fixed in 3% glutaralde-
hyde in PBS for 2 h, washed 5 times with 0.1 M 
cacodylate buffer, and post-fixed with 1% OsO4 
in 0.1 M cacodylate buffer containing 0.1% 
CaCl2 for 1.5 h at 4°C. Cells were dehydrated in 
a graded alcohol series and embedded in epoxy 
resin. Ultra-thin sections were cut and stained 
with uranyl acetate and lead citrate. Images 
were taken using a JEM-1200EX II electron 
microscope (JEOL, Tokyo, Japan). Each experi-
ment was repeated 3 times, and 3 images were 
obtained in each group for each experiment.
DQ-BSA uptake assay
A DQ-green-BSA dye was used to test lysosom-
al proteolytic degradation. H1 and Melmet 1 
cells treated with PBS (control) or 3 µM TFP for 
24 h were incubated with DQ-green-BSA (5 μg/
mL, Invitrogen) at 37°C for 1 h. Cells were rin- 
sed, fixed with 4% paraformaldehyde at room 
temperature for 15 min and stained with DAPI. 
Images were obtained using a Leica TCS SP5 
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confocal microscope (Leica Microsystems). Ea- 
ch experiment was repeated 3 times, and 3 
images were obtained in each group for each 
experiment.
Cathepsin B activity assay
The Cathepsin B Activity Assay Kit (Abcam, 
Cambridge, UK) was used to test the activity 
of cathepsin B as described previously [20]. 
Briefly, after treatment with PBS (control) or 3 
µM TFP for 24 h, cells were lysed in lysis buffer, 
and supernatants were incubated with cathep-
sin-B substrates (Ac-RR-AFC) at 37°C for 1.5 h. 
Fluorescence due to the cleaved substrate was 
measured on a scanning multiwell spectropho-
tometer (Victor 3 1420 multi-label counter, 
Perkin Elmer) at excitation/emission wavele- 
ngths = 400/505 nm. The results are repre-
sented as relative fluorescent units. Each ex- 
periment was repeated 3 times. 
Lysosomal membrane stability
Lysosomal membrane stability was tested 
using acridine orange (AO; Sigma-Aldrich, USA) 
[23]. AO is a lysosomotropic weak base and will 
accumulate in acidic compartments. The con-
centration of AO is high in intact lysosomes, 
and emits red fluorescence. If the lysosomal 
membrane is impaired, AO concentrations are 
low, and emits green fluorescence. H1 and 
Melmet 1 cells were incubated with AO solution 
(5 μg/mL) in complete DMEM for 15 min at 
37°C. Cells were exposed to PBS or 3 μM TFP 
for 60 min. Images were taken with a Leica TCS 
SP5 confocal microscope (Leica Microsystems). 
Each experiment was repeated 3 times, and 3 
random images were taken in each group for 
each experiment.
Immunofluorescence
After treatment with PBS, 3 μM or 6 μM TFP 
for 24 h, H1 and Melmet 1 cells were rinsed 3 
times with PBS, fixed with 4% paraformalde-
hyde at room temperature for 15 min and per-
meabilized with 0.2% Triton X-100 for 20 min. 
Cells were blocked with 5% BSA (Sigma), incu-
bated with primary antibodies for galectin 3 
(1:400, Cell Signaling Technology) or LAMP2 
(1:100, Abcam, Cambridge, UK) overnight, and 
then stained with goat anti-rabbit IgG (Alexa 
Fluor 555, Thermo Fisher Scientific) for 1 h. 
Finally, the samples were mounted in mounting 
medium (Thermo Fisher Scientific). Three ran-
dom fields were examined with a Leica TCS SP5 
confocal microscope (Leica Microsystems). Ea- 
ch experiment was repeated 3 times. 
Transfection of siRNA
H1 and Melmet 1 cells were transfected with 
siRNA using lipofectamine 2000 according to 
the manufacturer’s protocol. The final con- 
centration of siRNAs was 20 nM. Sequences 
for the siRNAs used were the following: control, 
5’-UUCUCCGAACGUGUCACGUTT-3’, STAT3, 5’- 
GUUCAUCUGUGUGACACCATT-3’ (Genepharma, 
Shanghai, China). Western blot analysis was 
used to assess the knockdown efficiency of 
siRNA.
Lactate dehydrogenase (LDH) assay 
Cell death was detected by measuring the 
release of LDH from the cytosol into the super-
natant, using the Cytotoxicity Detection Kit 
(Roche Applied Science, Indianapolis, IN, USA) 
according to the manufacturer’s instructions. 
After treatment with PBS, 6 μM TFP, 10 μM 
Pepstatin A, 20 nM siControl or 20 nM siSTAT3 
for 48 h, H1 and Melmet 1 cells in each group 
were lysed with lysis buffer (2% Triton X-100). 
Supernatants were collected and measured at 
490 nm on a scanning multiwell spectropho-
tometer (Victor 3 1420 multi-label counter, 
Perkin Elmer). In each group, the percentage 
cytotoxicity was calculated from the released 
LDH divided by the total amount of LDH. Each 
experiment was repeated 3 times. 
Statistical analysis
Unpaired, two-tailed t-tests were performed 
using SPSS software v13.0 (SPSS Inc., Chicago, 
IL). Kaplan-Meier survival analysis and the 
Mantel-Cox log-rank test were performed in 
GraphPad Prism 6 (La Jolla, CA, USA), to assess 
survival differences between animal groups. 
Results are presented as the mean ± standard 
error (SE). P-values ≤ 0.05 were considered sta-
tistically significant.
Results 
TFP treatment inhibits growth of melanoma 
brain metastatic cells in vitro
We first tested response to TFP on a panel of 
human metastatic melanoma cell lines using 
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several growth assays in vitro. First, increasing 
TFP concentrations decreased the cell viability 
of all 4 melanoma cell lines (Figure 1A), and the 
IC50 concentrations for the H1, H3, Melmet 1 
and Melmet 5 cells were 7.2 µM, 4.1 µM, 6.5 
µM and 3.3 µM, respectively. Second, growth 
curves generated with cell counting data dem-
onstrated that cell proliferation was inhibited 
by TFP treatment relative to controls (Figure 
1B). Third, colony formation was inhibited by 
TFP for all 4 cell lines (Figures 1C, 1D and S1). 
TFP at 6 µM reduced colony number by > 50% 
relative to controls. 
Finally, we examined the effect of TFP on 3D 
tumor spheroid growth. In a pilot study using 3 
µM and 6 µM TFP, TFP at 3 µM was not able to 
inhibit spheroid growth (data not shown), likely 
due to low drug penetrance into the spheroids. 
We thus decided to use 5 µM and 10 µM for 
Figure 1. TFP inhibits in vitro growth of melanoma brain metastatic cells. (A) Cell viability of H1, H3, Melmet 1 and 
Melmet 5 cells after treatment with 0-30 µM TFP for 72 h. (B) Growth curves generated using cell counting for H1 
and Melmet 1 cells over 96 h, after treatment with 0 µM (Ctrl), 3 µM or 6 µM TFP. (C) Image of colony formation 
assay for H1 and Melmet 1 cells at day 14, after pretreatment with 0 µM (Ctrl), 3 µM or 6 µM TFP for 24 h. (D) Quan-
tification of the number of colonies seen in (C). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (E) Growth 
of multicellular spheroids derived from H1 and Melmet 1 cells, after treatment with 0 µM (Ctrl), 3 µM or 6 µM TFP 
for 15 days. (F) Quantification of fold-change in spheroid growth seen in (E).
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this assay. At these concentrations, TFP signifi-
cantly inhibited tumor spheroid growth over a 
15-day time course (Figure 1E and 1F). 
TFP treatment decreases metastatic tumor 
burden in vivo and improves animal survival
Based on the in vitro results, we studied the 
anti-tumor effects of TFP in vivo using a well-
established animal model of human melanoma 
brain metastasis [24]. MRI performed at weeks 
4 and 6 after tumor cell injections, showed a 
significant decrease in total tumor numbers 
and total tumor volumes in the brains of TFP 
treated mice, as compared to untreated mice 
(Figure 2A). Quantification performed in OsiriX 
verified these results (Figure 2B and 2C). TFP 
also improved animal survival, which was 53.0 
days vs 44.5 days, TFP treated vs untreated 
animals, respectively (P < 0.01, Figure 2D).  
H&E-stained sections of mouse brains con-
firmed that TFP treated mice exhibited fewer 
and smaller brain metastatic tumors compared 
to untreated mice (Figure 2E). Ki67 immunohis-
tochemical staining of sections demonstrated 
Figure 2. TFP decreases brain metastatic tumor burden in vivo and prolongs animal survival. (A) Development of 
H1_DL2 brain metastases assessed by T1-weighted (before and after contrast injections) and T2-weighted MRI at 
weeks 4 and 6 after intracardial tumor cell injections. Scale bar = 25 mm. (B) Quantification of the mean tumor 
numbers in controls and treated animals at weeks 4 and 6. *P < 0.05, ****P < 0.0001. (C) Quantification of the 
mean tumor volumes in controls and treated animals at weeks 4 and 6. ****P < 0.0001. (D) Kaplan-Meier survival 
plot for tumor bearing animals treated with TFP or vehicle control (Mantel-Cox log-rank test). **P < 0.01. (E) Images 
of H&E stained brain tumor sections of untreated (top row) or TFP treated (bottom row) mice. Scale bar = 100 µm. 
(F) Images of Ki-67 stained brain tumor sections of untreated (top row) or TFP treated (bottom row) mice. Scale bars 
= 100 µm. (G) Quantification of Ki-67 stained brain tumor sections. **P < 0.01.
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that tumor cell proliferation decreased under 
TFP treatment (57.33% ± 5.04% vs 13.00% ± 
3.22% in untreated brain metastasis to in TFP 
treated brain metastasis; Figure 2F and 2G, P < 
0.01).
TFP treatment inhibits autophagy of melano-
ma brain metastatic cells
We have previously shown in GBM cell lines 
that one mechanism of TFP inhibition of cell 
growth is through inhibition of autophagy [20]. 
We therefore performed several assays to 
determine whether TFP also caused autophagy 
in human melanoma brain metastatic cells. 
Under TFP treatment, the levels of the autopha-
gy related protein LC3B-II increased, as well as 
for P62, one of the most important long-lived 
proteins critical for the process (Figures 3A and 
S2). Immunohistochemical staining of brain 
sections from tumor bearing animals also dem-
Figure 3. TFP inhibits autophagy in melanoma brain metastatic cells. (A) Western blot of LC3B, P62 and GAPDH 
(loading control) in H1 and Melmet 1 cells treated with 0 µM (Ctrl), 3 µM or 6 µM TFP for 24 h. Images of immuno-
histochemical staining and quantification of the expression of (B) LC3B and (C) P62 and in brain tumor sections 
from untreated (Ctrl) and TFP treated mice. Scale bars = 100 µm. *P < 0.05, **P < 0.01. (D) Confocal images of 
autophagic flux in H1 and Melmet 1 cells, as visualized with RFP-GFP-LC3, 48 h after treatment with either 0 µM 
(Ctrl) or 3 µM TFP. The increase in GFP (green) relative to RFP (red) after TFP treatment shows inhibition of autopha-
gic flux. The quantification is shown in Figure S3. Scale bar = 10 µm. (E) Confocal images of lysosomes in H1 and 
Melmet 1 cells, stained with LysoTracker Red, 24 h after treatment with either 0 µM (Ctrl) or 3 µM TFP. Cell nuclei 
were counterstained with DAPI (blue). Scale bars = 10 µm. (F) Transmission electron micrographs, showing the ultra-
structure of H1 cells treated with 0 mM (Ctrl) or 3 µM TFP. In TFP treated cells, electron dense vacuoles accumulated 
(red arrows). Scale bars = 1 µm. (G) Confocal images of the DQ-BSA uptake assay (green) in H1 and Melmet 1 cells. 
Cell nuclei were counterstained with DAPI (blue). Scale bar = 10 µm. (H) Quantification of the fluorometric assay, 
showing the relative cathepsin B activity in H1 and Melmet 1 cells treated with 0 µM (Ctrl), 3 µM or 6 µM TFP for 24 
h. **P < 0.01, ***P < 0.001.
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onstrated that TFP treatment increased the 
expression of LC3B and P62 in brain metasta-
ses (Figure 3B and 3C). Finally, using the RFP-
GFP-LC3 probe, we found that the autophagic 
flux was interrupted after TFP treatment as 
there was no loss of GFP fluorescence indicat-
ing a shift to the lower pH autolysosome 
(Figures 3D and S3).
Next, we explored which phase of autophagic 
flux was inhibited. The upregulation of P62 may 
be due to TFP blocking either of two processes: 
the fusion of lysosomes with autophagosomes 
or the degradation of the autolysosomes. We 
used LysoTracker Red to stain the lysosomes 
before and after TFP treatment. Our results 
showed that in TFP treated cells, the intensity 
of red florescence decreased significantly com-
pared to that in the control group. The lyso-
somes also changed morphologically, appear-
ing to be enlarged (Figure 3E). Our results thus 
indicated that TFP interfered with the function 
of the lysosomes. 
TEM was used to observe potential changes in 
the ultrastructure of tumor cells after TFP treat-
ment. TFP caused accumulation of electron 
dense vesicles, which is consistent with dam-
aged lysosomes (Figures 3F and S4). The mor-
phological changes observed on TEM were fur-
ther supported by results of the DQ-BSA uptake 
assay performed on cells in vitro. DQ-BSA is a 
substrate of lysosomal proteases, and the deg-
radation of this substrate generates small par-
ticles with green florescence in functioning 
lysosomes. TFP treatment decreased green 
fluorescence, an indication of non-functioning 
lysosomes (Figure 3G). 
Finally, the activity of cathepsin B, a critical 
lysosomal protease, was also reduced in TFP 
treated cells, as indicated by reduced GFP lev-
els from the cleaved substrate Ac-RR-AFC after 
TFP treatment (Figure 3H). Taken together, our 
results demonstrated that TFP treatment 
impaired the function of lysosomes and as a 
result, autophagy was inhibited.
TFP treatment causes lysosomal membrane 
permeabilization in melanoma brain meta-
static cells 
The results from the LysoTracker Red experi-
ments indicated that TFP treatment caused 
enlargement of lysosomes (Figure 3E). 
Immunofluorescence staining with LAMP2, a 
lysosome-associated membrane protein, con-
firmed the accumulation of enlarged lysosomes 
in H1 and Melmet 1 cells under TFP treatment 
(Figure S5). The impaired function of the lyso-
somes in the presence of TFP (Figure 3G and 
3H) might further indicate that the drug causes 
lysosomal membrane permeabilization (LMP). 
Acridine orange staining, which detects intact 
membranes, decreased in TFP treated mela-
noma brain metastatic cells, demonstrating 
that lysosomal membranes had been compro-
mised (Figure 4A). 
Figure 4. TFP treatment causes lysosomal membrane permeabilization in melanoma brain metastatic cells. (A) 
Confocal images of acridine orange staining to determine lysosomal membrane stability in H1 and Melmet 1 cells 
treated with 0 µM (Ctrl), 3 µM or 6 µM TFP for 60 min. The red fluorescence decreased after treatment with 3 µM 
or 6 µM TFP, indicating impaired lysosomal membranes. Scale bar = 50 µm. (B) Confocal images of immunofluores-
cence staining for galectin-3 in H1 and Melmet 1 cell lines, before and after treatment with 6 µM TFP for 24 h. In 
untreated cells, galectin-3 was distributed evenly in the cytoplasm, while in TFP-treated cells, galectin-3 was associ-
ated with punctate structures in the enlarged lysosomes. Scale bar = 10 µm.
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We also examined the integrity of these en- 
larged lysosomes using immunofluorescence 
staining with galectin-3, which binds to β-ga- 
lactosides on the luminal glycoproteins of the 
ruptured membranes of endosomes or lyso-
somes [25]. In untreated cells, galectin-3 was 
distributed evenly in the cytoplasm. However, in 
TFP-treated melanoma cells, galectin-3 formed 
punctate structures in the enlarged lysosomes 
(Figure 4B). Taken together, the results indicat-
ed that TFP damaged lysosomal membranes, 
which led to LMP.
Lysosomal membrane permeabilization-
induced cell death is STAT3 dependent in 
melanoma brain metastatic cells
Previous studies have shown that LMP which 
initiates a cascade of events leading to the deg-
radation of vital cellular proteins/components 
can cause cell death [26, 27]. We thus used 
release of LDH as a measure of the cytotoxicity 
of TFP. Treatment of cells with TFP resulted in 
a significant increase in the release of LDH 
(Figure 5A). To test whether the cytotoxic ef- 
Figure 5. LMP-induced cell death is STAT3 dependent in melanoma brain metastatic cells. (A) LDH release in H1 and 
Melmet 1 cells, either untreated (Ctrl) cells, or after treatment with 6 µM TFP, 10 µM pepstatin A or combined treat-
ment. (B) Western blot analysis of phosphorylated STAT3 after treatment of the H1 and Melmet 1 cells with 0 μM, 3 
μM or 6 μM TFP for 24 h. (C) Confocal images of immunofluorescence staining for galectin-3 in the H1 and Melmet 
1 cell lines, treated with 6 μM TFP+siCtrl or 6 μM TFP+siSTAT3 for 24 h. LMP is inhibited after STAT3 knockdown. 
Scale bar = 10 µm. (D) LDH release in H1 and Melmet 1 cells, either untreated cells (Ctrl), or cells treated with 6 
µM TFP, siSTAT3 or combined treatment. siSTAT3+TFP treatment reduced LDH release compared to TFP treatment 
alone. *P < 0.05, **P < 0.01, ***P < 0.001.
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fects of TFP were dependent on LMP, we com-
bined TFP treatment with an inhibitor of cathep-
sin D, pepstatin A. LDH release decreased 
significantly in TFP-treated cells in the presence 
of pepstatin A (Figure 5A). These results sug-
gested that TFP-induced cell death is LMP- 
dependent. 
Recent studies have found that the transcrip-
tion factor STAT3 might mediate LMP [28-30], 
through activation of the expression of cathep-
sins and suppression of the endogenous 
cathepsin inhibitor, Spi2A. Treatment with TFP 
increased the levels of phosphorylated STAT3, 
its active form, in melanoma brain metastatic 
cells in a dose-dependent manner (Figure 5B). 
The total protein levels of STAT3 were however 
not affected. To test whether the cell death 
caused by TFP is STAT3 dependent, we trans-
fected H1 and Melmet 1 cell lines with siRNAs 
targeting STAT3 (Figure S6). H1- and Melmet 
1-siSTAT3 cells had less damage to lysosomal 
membranes (highlighted with galectin-3) under 
TFP treatment compared to TFP treatment of 
the parental cell lines (Figure 5C). We also 
found that H1- and Melmet 1-siSTAT3 cells 
released significantly less LDH after TFP treat-
ment relative to TFP treated parental cell lines 
(Figure 5D). In summary, our data suggest that 
TFP treatment causes LMP-induced cell death, 
which is STAT3 dependent.
Discussion 
Melanoma has a tremendous propensity to 
metastasize to the brain. Despite aggressive 
treatment, the prognosis for patients with mel-
anoma brain metastasis remains poor. A chal-
lenge even today with the current crop of tar-
geted drugs is that most are still too large to 
penetrate the BBB. Recently, drug repurposing 
has gained increased attention in cancer treat-
ment [31]. Repurposed drugs often have other 
mechanisms of action beyond the purpose for 
which they were developed, and therefore may 
be exploited for other maladies including can-
cer. These drugs often have documented safety 
profiles, after many years of clinical use. Drug 
repurposing also cuts through years of labori-
ous and expensive drug development [32, 33]. 
In the current work, we show that the antipsy-
chotic drug trifluoperazine (TFP) may be repur-
posed for the treatment of melanoma brain 
metastasis. Using a well-established animal 
model for melanoma brain metastasis, we 
found that TFP treatment decreased the brain 
metastatic tumor burden, and improved animal 
survival. 
A characteristic essential for efficacy of drugs 
in the treatment of brain metastasis is the abil-
ity to penetrate an intact BBB [34]. Early in 
brain metastatic tumor progression, the brain 
lesions are too small to destroy the BBB, and 
they are thus not visible on contrast enhanced 
MRI [8]. Due to its favorable size (407.5 Da), 
TFP is able to penetrate an intact BBB, as previ-
ously shown by us [20] and others [15, 35]. TFP 
may thus be an attractive adjuvant to current 
established therapies for melanoma brain 
metastasis.
Our work showed that TFP decreased cell viabil-
ity, cell proliferation and spheroid growth. TFP 
caused lysosomal membrane permeabilization 
(LMP), which is characterized by decreased 
cytosolic but increased lysosomal pH, per-
turbed iron homeostasis, defects in lysosomal 
cytoprotective factors and release of hydrolas-
es into the cytosol. More importantly, LMP is 
associated with cell death [26]. We found that 
TFP treatment also induced cell death, and fur-
thermore the process appeared to be mediated 
by the transcription factor STAT3. Our results, 
that TFP causes LMP and cell death through 
STAT3, corroborate the work of previous stud-
ies [29]. 
STAT3 is a cell proliferation-related transcrip-
tion factor that regulates numerous apoptosis-
related proteins, including Bcl-2, Bcl-xL, Mcl-1, 
and cyclin D1. STAT3 is also reported to func-
tion as an oncogene in tumorigenesis and 
tumor development [36]. Recently, several stu- 
dies have reported that STAT3 controls the pro-
cess of LMP, which leads to cell death [28-30]. 
The underlying mechanism may be that STAT3 
at least partially inhibits the transcriptional 
activity of transcription factor EB (TFEB), which 
is involved in lysosome biogenesis [37]. STAT3 
thus renders TFEB unable to facilitate lysosom-
al repair and biogenesis, subsequently contrib-
uting to further lysosomal instability and cell 
death [30]. These studies also suggest that 
STAT3 could have other, yet unidentified roles, 
in addition to being oncogenic. However, we 
have not investigated whether STAT3 has an 
oncogenic role in our brain metastasis model.
Trifluoperazine prolongs the survival of experimental brain metastases
556 Am J Cancer Res 2020;10(2):545-563
In summary, TFP showed efficient anti-tumor 
effects and increased survival in an experimen-
tal brain metastasis model. STAT3 and LMP 
mediate the response of cells to TFP. Our data 
should therefore encourage further investiga-
tion into the efficacy of TFP as an adjuvant ther-
apy for the treatment of melanoma brain me- 
tastases in the clinical setting.
In this study we report for the first time that TFP 
inhibited the growth of melanoma brain metas-
tases and prolonged animal survival after injec-
tion of tumor cells. On the molecular level, TFP 
was cytotoxic to melanoma brain metastases 
based on TFP-induced lysosomal membrane 
permeabilization and cell death appeared to be 
STAT3 dependent. Our study provided more 
basis for further clinical investigation of TFP as 
an efficient therapy for patients with brain me- 
tastases.
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Figure S1. Images and quantification of colony formation assay for H3 and Melmet 5 cells at day 14, after pretreat-
ment with 0 µM (Ctrl), 3 µM or 6 µM TFP for 24 h. **P < 0.01; ****P < 0.0001.
Figure S2. Western blot of LC3B, P62 and GAPDH (loading control) in H3 and Melmet 5 cells treated with 0 µM (Ctrl), 
3 µM or 6 µM TFP for 24 h.
Figure S3. Quantification of autophagic flux in H1 and Melmet 1 cells, 48 h after treatment with either 0 µM (Ctrl) 
or 3 µM TFP. 
Figure S4. Transmission electron micrographs, showing the ultrastructure of Melmet 1 cells treated with 0 µM (Ctrl) 
or 3 µM TFP. In TFP treated cells, electron dense vacuoles accumulated (red arrows). Scale bars = 1 µm.
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Figure S5. Confocal images showing immunofluorescence staining of the lysosome-associated membrane protein 
LAMP2 in H1 and Melmet 1 cells, either untreated or treated with 3 µM TFP for 24 h. Scale bar = 10 µm.
Figure S6. Western blot analysis showing knockdown of STAT3 in H1 and Melmet 1 cells, treated either with siCtrl 
or with siRNA for STAT3 (siSTAT3).
